|
- 2017
Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA StudyDOI: 10.2174/1874312901711010123 Keywords: Rheumatoid arthritis, Etanercept, Adalimumab, Infliximab, Dose escalation, Intensification Abstract: To compare anti-TNF dose escalation, DMARD and/or glucocorticoid intensification, switches to another biologic, and drug and drug-related costs over 12 and 18 months for rheumatoid arthritis (RA) patients initiating etanercept (ETN), adalimumab (ADA), or infliximab (IFX) in routine clinical practice across Canada
|